Pharvaris (NASDAQ:PHVS) Trading Up 5.8% – Here’s Why

Pharvaris N.V. (NASDAQ:PHVS) shares rose 5.8% on Friday . The stock traded as high as $39.94 and last traded at $39.69. Approximately 130,515 shares traded hands during trading, a decline of 66% from the average session volume of 384,517 shares. The stock had previously closed at $37.51.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris reported that once-daily extended-release deucrictibant reduced HAE attack rates by 83% versus placebo in the pivotal Phase 3 CHAPTER-3 trial. The result was statistically significant, with a p-value below 0.0001, and the trial met its primary and secondary endpoints. The company plans to begin regulatory submissions in the first half of 2027. CHAPTER-3 trial report
• Positive Sentiment: The results strengthen Pharvaris’ competitive position in HAE because the company is developing oral therapies for both prophylactic and on-demand use. Analysts believe oral convenience, combined with the efficacy data, could help Pharvaris gain market share. RBC HAE market-share analysis
• Positive Sentiment: Analyst sentiment remains favorable. Leerink Partners initiated or reiterated a Buy-equivalent rating with a $65 price target, while RBC Capital maintained its Buy/Outperform view and raised its target to $62. Citizens JMP also increased its target to $79 and maintained Market Outperform. HC Wainwright reaffirmed Buy with a $60 target, and Wedbush maintained Outperform. Leerink Partners rating
• Neutral Sentiment: The bullish outlook remains dependent on regulatory approval, successful commercialization and competition from established HAE therapies. Pharvaris is still a clinical-stage, loss-making company, so future valuation will remain sensitive to clinical and regulatory developments.
• Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The sale may create a modest insider-selling overhang, although it does not alter the positive clinical results. Pharvaris insider sale

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Wedbush set a $50.00 price objective on Pharvaris and gave the company an “outperform” rating in a research report on Wednesday. HSBC raised Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. UBS Group set a $79.00 price target on shares of Pharvaris in a research note on Wednesday. Finally, Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research note on Wednesday. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $59.50.

Pharvaris Stock Performance

The company has a market cap of $2.52 billion, a PE ratio of -12.60 and a beta of -2.33. The company has a fifty day moving average of $35.01 and a two-hundred day moving average of $31.34.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, equities analysts forecast that Pharvaris N.V. will post -3.1 EPS for the current year.

Insider Activity

In other Pharvaris news, CEO Berndt Modig sold 2,292 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $34.77, for a total value of $79,692.84. Following the completion of the sale, the chief executive officer owned 130,625 shares of the company’s stock, valued at $4,541,831.25. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Peng Lu sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $40.68, for a total value of $610,200.00. Following the transaction, the president owned 65,179 shares of the company’s stock, valued at $2,651,481.72. This trade represents a 18.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 133,655 shares of company stock valued at $4,798,202. Company insiders own 11.84% of the company’s stock.

Institutional Trading of Pharvaris

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP purchased a new stake in Pharvaris in the 2nd quarter valued at about $41,000. JPMorgan Chase & Co. increased its holdings in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period. Barclays PLC bought a new stake in Pharvaris during the 4th quarter valued at $77,000. CoreCap Advisors LLC purchased a new stake in shares of Pharvaris in the 2nd quarter worth $93,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Pharvaris in the 4th quarter worth $139,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.